Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition.

Centre Hospitalier Universitaire, Amiens30 enrolled

Overview

Fibroblast growth factor 23 (FGF23) is a recently discovered phosphaturic hormone produced by osteocytes. It is involved in phosphate-calcium metabolism (via its phosphaturic action and inhibition of 1,25-OH vitamin D). There are no published studies on the role of FGF23 in undernourished anorexic adolescents taking oral phosphorus supplements.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Malnutrition

Eligibility

Sex: ALLMin age: 11 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adolescents aged from 11 to 17 * Follow-up or hospitalisation for anorexia * Overt undernutrition (clinical signs of undernutrition, body mass index and the Waterlow index) * Social security coverage Exclusion Criteria: * Known pre-existing renal disorders * Known constitutional disorders of phosphate-calcium metabolism * Adult patients, legal guardianship, incarceration

Locations (1)

CHU Amiens

Amiens, France

RECRUITING

Outcomes

Primary Outcomes

FGF23

Change in the FGF23 level (U/ml) with regard to the exogenous phosphorus intake (doses of Phosphoneuros®, expressed in mg/kg/day)

Time frame: at inclusion and then once a month for 6 months.

Central Contacts

Lydia LICHTENBERGER, PhD

CONTACT

+33 3 22 08 76 60 lichtenberger.lydia@chu-amiens.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.